Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study

Trial Profile

Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Biotin (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms MS-SPI
  • Sponsors MedDay Pharmaceuticals
  • Most Recent Events

    • 28 Oct 2017 Results of a sub-group analysis assessing the effect of MD1003 in spinal progressive multiple sclerosis, presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Oct 2017 36-month follow-up results presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 26 Oct 2017 According to a MedDay Pharmaceuticals media release, additional data will be present at the 7th joint ECTRIMS-ACTRIMS meeting, 25-28 October 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top